Panelists discuss the key disease and patient factors considered when choosing between triplet and quadruplet induction regimens for patients with transplant-ineligible multiple myeloma, as well as the unmet needs that persist in the treatment landscape for both transplant-eligible and ineligible populations.
Dr Ajai Chari to Dr Callander: What factors (disease or patient) do you consider when deciding between a triplet vs quadruplet induction regimen for those who are transplant ineligible?
Dr Ajai Chari to Dr Raje: What unmet needs still exist in the treatment paradigm of newly diagnosed multiple myeloma, both transplant eligible and ineligible?